Humacyte Inc Revenue Growth Rates (HUMA), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Humacyte Inc   (NASDAQ: HUMA)
 

HUMA's Revenue Growth by Quarter and Year

Humacyte Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

HUMA Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June -4.75
1st Quarter March 9.02
FY 4.27

HUMAs Annual Revenue
Humacyte Inc 's Revenue in the fiscal year 2025 $ 40.80 millions
Humacyte Inc 's Revenue in the fiscal year 2024 $ 3.92 millions
Humacyte Inc 's Revenue in the fiscal year 2023 $ -0.26 millions
Humacyte Inc 's Revenue in the fiscal year 2022 $ 1.57 millions
Humacyte Inc 's Revenue in the fiscal year 2021 $ 1.26 millions




HUMA Revenue second quarter 2026 Y/Y Growth Comment
Humacyte Inc in the second quarter 2026 recorded of $ -4.75 millions.

Looking into second quarter 2026 results within Biotechnology & Pharmaceuticals industry 40 other companies have achieved higher Revenue growth. While Humacyte Inc ' s Revenue no change of 0% ranks overall at the positon no. 2663 in the second quarter 2026.


HUMA Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 557.5 % - -
3rd Quarter September - 353.33 % - -
2nd Quarter June - - - -
1st Quarter March -41.62 % 25650 % - -
FY   - 940.82 % - -

Financial Statements
Humacyte Inc 's second quarter 2026 Revenue $ -4.75 millions HUMA's Income Statement
Humacyte Inc 's second quarter 2025 Revenue $ -0.45 millions Quarterly HUMA's Income Statement


HUMA Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 342.02 % 204.76 % -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March -57.13 % 382.81 % - -
FY (Year on Year)   - 940.82 % - -


Back to HUMA Growth rate Comparisons >> Back to HUMA Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #41
Healthcare Sector #380
Overall #2663

Revenue Y/Y Growth Statistics
High Average Low
5499.51 % 1644.03 % 56.29 %
(Sep 30 2025)   (Jun 30 2026)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #41
Healthcare Sector #380
Overall #2663
Revenue Y/Y Growth Statistics
High Average Low
5499.51 % 1644.03 % 56.29 %
(Sep 30 2025)   (Jun 30 2026)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Humacyte Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


HUMA's II. Quarter Q/Q Revenue Comment
Recent accomplishment of -4.75 millions by Humacyte Inc come out even worse considering the 9.02 millions a quarter before.

Within Biotechnology & Pharmaceuticals industry Humacyte Inc achieved highest sequential Revenue growth. While Humacyte Inc 's Revenue growth quarter on quarter, overall rank is .


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


HUMA's II. Quarter Q/Q Revenue Comment
Recent accomplishment of -4.75 millions by Humacyte Inc come out even worse considering the 9.02 millions a quarter before.

Within Biotechnology & Pharmaceuticals industry Humacyte Inc achieved highest sequential Revenue growth. While Humacyte Inc 's Revenue growth quarter on quarter, overall rank is .


Humacyte Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 30.07 $ 34.38 $ 40.80 $ 22.96 $ 19.24
Y / Y Revenue Growth (TTM) 56.29 % 78.1 % 942.22 % 5499.51 % -
Year on Year Revenue Growth Overall Ranking # 9 # 7 # 7 # 5 # 0
Seqeuential Revenue Change (TTM) -12.51 % -15.75 % 77.73 % 19.31 % -0.31 %
Seq. Revenue Growth (TTM) Overall Ranking # 2663 # 46 # 15 # 17 # 18


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Humacyte Inc 's cumulative twelve months Revenue were $ 30 millions, company would post below average annual Revenue growth of -0.31% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Humacyte Inc 's Revenue growth from the 9.02% growth in Mar 31 2026.

Among companies within the Healthcare sector 3 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 7 to 9.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 41
Healthcare Sector # 4
Overall # 9

Revenue TTM Y/Y Growth Statistics
High Average Low
5499.51 %
 1644.03 %
56.29 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 41
Sector # 380
S&P 500 # 2663
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Humacyte Inc 's cumulative twelve months Revenue were $ 30 millions, company would post below average annual Revenue growth of 56.29% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Humacyte Inc 's Revenue growth from the 9.02% growth in Mar 31 2026.

Among companies within the Healthcare sector 3 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 7 to 9.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 41
Healthcare Sector # 4
Overall # 9

Revenue TTM Y/Y Growth Statistics
High Average Low
5499.51 %
1644.03 %
56.29 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 41
Sector # 380
S&P 500 # 2663




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
HUMA's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue no change for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
EBR Systems, Inc.1,453.92%$ 1,453.919 millions
Safe Pro Group Inc 1,336.15%$ 1,336.152 millions
Capforce Inc 1,150.00%$ 1,150.000 millions
Crispr Therapeutics Ag1,041.37%$ 1,041.368 millions
Arvinas Inc 1,014.73%$ 1,014.732 millions
Abeona Therapeutics Inc 697.48%$ 697.477 millions
Nuvation Bio Inc 644.35%$ 644.350 millions
Tonix Pharmaceuticals Holding Corp 577.88%$ 577.878 millions
Allogene Therapeutics Inc 567.50%$ 567.500 millions
Brightspring Health Services Inc 555.52%$ 555.518 millions
Bullfrog Ai Holdings Inc 547.64%$ 547.638 millions
Northwest Biotherapeutics Inc516.03%$ 516.031 millions
Vistagen Therapeutics Inc 504.92%$ 504.918 millions


About Humacyte Inc Revenue Growth Rates (HUMA), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Humacyte Inc (CIK 1818382).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-347022
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Humacyte Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.